BACKGROUND: Assays used for discovery of biomarkers should be robust and high-throughput, capable of analyzing a sufficiently large number of samples over a sufficiently long period of time with good precision. METHODS: We evaluated the analytical performance of the Bio-Plex Pro™ Human Cancer Biomarker Panel 1, a 16-plex multiplex immunoassay, in serum for composite profiling of angiogenic factors. Because prostate cancer progression and metastasis are pathological events closely linked to angiogenesis, serum angiogenic factors are ideal candidates as prognostic biomarkers. RESULTS: Our 5-day evaluation indicated that all 16 assays in the panel had good reproducibility (total precisions over 5 independent plates in 5 days of <20%), adequate sensitivity (LOQs of majority of the assays less than 100 pg/ml), and wide dynamic ranges (linearity of majority of the assays spanning across 3 logs in concentrations). CONCLUSIONS: Applying the panel to sera from prostate cancer patients with Gleason scores of 6, 7, 8-10, tumor stages that correlated with clinical outcome, we identified that the levels of sTIE-2, a soluble form of the transmembrane tyrosine kinase receptor for angiopoietins, were increased in patients with Gleason score of 8-10. Future studies are necessary to determine whether sTIE-2 could be used as a prognostic biomarker for identifying aggressive prostate cancer.
BACKGROUND: Assays used for discovery of biomarkers should be robust and high-throughput, capable of analyzing a sufficiently large number of samples over a sufficiently long period of time with good precision. METHODS: We evaluated the analytical performance of the Bio-Plex Pro™ HumanCancer Biomarker Panel 1, a 16-plex multiplex immunoassay, in serum for composite profiling of angiogenic factors. Because prostate cancer progression and metastasis are pathological events closely linked to angiogenesis, serum angiogenic factors are ideal candidates as prognostic biomarkers. RESULTS: Our 5-day evaluation indicated that all 16 assays in the panel had good reproducibility (total precisions over 5 independent plates in 5 days of <20%), adequate sensitivity (LOQs of majority of the assays less than 100 pg/ml), and wide dynamic ranges (linearity of majority of the assays spanning across 3 logs in concentrations). CONCLUSIONS: Applying the panel to sera from prostate cancerpatients with Gleason scores of 6, 7, 8-10, tumor stages that correlated with clinical outcome, we identified that the levels of sTIE-2, a soluble form of the transmembrane tyrosine kinase receptor for angiopoietins, were increased in patients with Gleason score of 8-10. Future studies are necessary to determine whether sTIE-2 could be used as a prognostic biomarker for identifying aggressive prostate cancer.
Authors: S Signoretti; R Montironi; J Manola; A Altimari; C Tam; G Bubley; S Balk; G Thomas; I Kaplan; L Hlatky; P Hahnfeldt; P Kantoff; M Loda Journal: J Natl Cancer Inst Date: 2000-12-06 Impact factor: 13.506
Authors: H Kuniyasu; P Troncoso; D Johnston; C D Bucana; E Tahara; I J Fidler; C A Pettaway Journal: Clin Cancer Res Date: 2000-06 Impact factor: 12.531
Authors: I Osman; H I Scher; M Drobnjak; D Verbel; M Morris; D Agus; J S Ross; C Cordon-Cardo Journal: Clin Cancer Res Date: 2001-09 Impact factor: 12.531
Authors: Darshana Jani; John Allinson; Flora Berisha; Kyra J Cowan; Viswanath Devanarayan; Carol Gleason; Andreas Jeromin; Steve Keller; Masood U Khan; Bill Nowatzke; Paul Rhyne; Laurie Stephen Journal: AAPS J Date: 2015-09-16 Impact factor: 4.009
Authors: Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto Journal: Target Oncol Date: 2013-03-01 Impact factor: 4.493
Authors: Jin Song; Shiyong Ma; Lori J Sokoll; Rodrigo V Eguez; Naseruddin Höti; Hui Zhang; Phaedre Mohr; Renu Dua; Dattatraya Patil; Kristen Douglas May; Sierra Williams; Rebecca Arnold; Martin G Sanda; Daniel W Chan; Zhen Zhang Journal: Theranostics Date: 2021-04-15 Impact factor: 11.556
Authors: Rebecca L R Powell; Ian Ouellette; Ross W Lindsay; Christopher L Parks; C Richter King; Adrian B McDermott; Gavin Morrow Journal: Biores Open Access Date: 2013-06